Naslov
USE OF LINEZOLID IN NEUTROPENIC PATIENTS

Autori
Jakšić, Branimir

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
ACCADEMIA NAZIONALE DI MEDICINA INTERNATIONAL FORUM ON HEMATOLOGY / - , 2005

Skup
ACCADEMIA NAZIONALE DI MEDICINA INTERNATIONAL FORUM ON HEMATOLOGY

Mjesto i datum
Barcelona, Španjolska, 13.10.2005. - 15.10.2005

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Linezolid

Sažetak
Linezolid, an oxazolidinone antibacterial effective for the treatment of infections caused by Gram-positive pathogens has been associated with reversible thrombocytopenia and anemia, predominately in patients with serious infections treated beyond the recommended 28 days. In patients receiving myelosuppressive chemotherapy, additional bone marrow suppression may have clinical significance. Linezolid (600 mg) was compared to vancomycin (1 g) IV q12h for 10-28 days in a randomized, double-blind, multi-center trial in 605 patients with febrile neutropenia (absolute neutrophil count <500/mm3) and a proven or suspected Gram-positive infection. This study demonstrates that linezolid is associated with efficacy outcomes at least equivalent to those of vancomycin. Mean time to defervescence was shorter for linezolid than for vancomycin in modified ITT (MITT) and microbiologically evaluable (ME) subsets. Linezolid appeared to have a safety advantage based on the incidence of drug-related adverse event, drug-related episodes of renal failure, and all-causality episodes of renal failure. Importantly, linezolid did not have any negative effects on the recovery of hematologic parameters, which is a concern in this population. In conclusion, linezolid appears to offer a useful option for febrile neutropenic cancer patients who require treatment for proven or suspected gram-positive infections

Izvorni jezik
Engleski

POVEZANOST RADA